Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Ana C Garrido-CastroCristina SauraRomualdo Barroso-SousaHao GuoEva CiruelosBegoña BermejoJoaquin GaviláVioleta SerraAleix PratLaia ParéPamela CélizPatricia VillagrasaYisheng LiJennifer SavoieZhan XuCarlos L ArteagaIan E KropDavid B SolitGordon B MillsLewis C CantleyEric P WinerNancy U LinJordi RodonPublished in: Breast cancer research : BCR (2020)
NCT01790932 . Registered on 13 February 2013; NCT01629615 . Registered on 27 June 2012.